logo
Twitter
Discord
Email
logo
logo
MoonLake ImmunotherapeuticsNASDAQ - MLTX
Reports
Search reports
Name
Reporting Date
Filing Date
2024-09-30 10-Q2024-09-302024-11-07
2024-06-30 10-Q2024-06-302024-08-07
2023-12-31 10-K2023-12-312024-05-07
2024-03-31 10-Q2024-03-312024-05-07
2023-12-31 10-K2023-12-312024-02-29
2023-09-30 10-Q2023-09-302023-11-14
2023-06-30 10-Q2023-06-302023-08-10
2023-03-31 10-Q2023-03-312023-05-11
2022-12-31 10-K2022-12-312023-03-20
2022-09-30 10-Q2022-09-302022-11-14
2022-06-30 10-Q2022-06-302022-08-12
2022-03-31 10-Q2022-03-312022-05-16
2021-12-31 10-K2021-12-312022-02-17
2021-09-30 10-Q2021-09-302021-12-14
2020-12-31 10-K2020-12-312021-12-14
2021-09-30 10-Q2021-09-302021-11-12
2021-06-30 10-Q2021-06-302021-08-16
2021-03-31 10-Q2021-03-312021-05-21
2020-12-31 10-K2020-12-312021-03-31
2020-09-30 10-Q2020-09-302020-12-03
1
20 / page
About
Name
MoonLake Immunotherapeutics
Overview
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
Show More
CEO
Dr. Jorge Santos da Silva
Industry
Biotechnology
Exchange
NASDAQ
Listing Date
2020-10-20
Address
Dorfstrasse 29, Zug, 6300, Switzerland
Tel
41-415108022
Website
https://www.moonlaketx.com